1. Basis of Presentation and Significant Accounting Policies
The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company views its operations and manages its business in one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing technology. Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the three and six month interim periods ended June 30, 2019 and 2018.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2018, which are contained in the 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 25, 2019.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of revenues, research and development expenses and equity-based compensation expense.
The Company bases its estimates on historical experience and various other assumptions, including, in certain circumstances, future projections that management believes to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2019 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on February 25, 2019, except with respect to the Company’s lease accounting policy noted within the “Recently adopted accounting standards” section below.
Impact of Adopting ASC 842 on the Financial Statements
|
|
January 1, 2019
Prior to ASC 842 Adoption
|
|
|
ASC 842 Adjustment
|
|
|
January 1, 2019
As Adjusted
|
|
Consolidated Balance Sheet Data (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets
(1)
|
|
$
|
9,658
|
|
|
$
|
(553
|
)
|
|
$
|
9,105
|
|
Operating lease assets
(2)
|
|
$
|
—
|
|
|
$
|
26,087
|
|
|
$
|
26,087
|
|
Deferred rent
(3)(4)
|
|
$
|
1,026
|
|
|
$
|
(1,026
|
)
|
|
$
|
—
|
|
Deferred rent non-current
(3)
|
|
$
|
11,052
|
|
|
$
|
(11,052
|
)
|
|
$
|
—
|
|
Operating lease liabilities
(5)
|
|
$
|
—
|
|
|
$
|
4,930
|
|
|
$
|
4,930
|
|
Non-current operating lease liabilities
(5)
|
|
$
|
—
|
|
|
$
|
32,682
|
|
|
$
|
32,682
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Represents reclassification of prepaid rent to operating lease assets.
|
|
(2) Represents capitalization of operating lease assets and reclassification of equipment licenses from prepaid expenses to operating lease assets, offset by reclassification of deferred rent to operating lease assets.
|
|
(3) Represents reclassification of deferred rent and tenant incentives to operating lease assets.
|
|
(4) As of December 31, 2018, the deferred rent balance was $1,202, which included $176 of sublease income received prior to year-end but not due until January 1, 2019.
|
|
(5) Represents recognition of operating lease liabilities.
|
|
2. Property and Equipment, net
Property and equipment, net, consists of the following (in thousands):
|
|
As of
|
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2019
|
|
|
2018
|
|
Computer equipment
|
|
$
|
585
|
|
|
$
|
443
|
|
Furniture, fixtures and other
|
|
|
2,555
|
|
|
|
2,453
|
|
Laboratory equipment
|
|
|
10,157
|
|
|
|
8,964
|
|
Leasehold improvements
|
|
|
14,937
|
|
|
|
13,776
|
|
Construction work in process
|
|
|
1,280
|
|
|
|
239
|
|
Total property and equipment, gross
|
|
|
29,514
|
|
|
|
25,875
|
|
Accumulated depreciation
|
|
|
(9,358
|
)
|
|
|
(7,375
|
)
|
Total property and equipment, net
|
|
$
|
20,156
|
|
|
$
|
18,500
|
|
Depreciation expense for the three and six months ended June 30, 2019 was $1.0 million and $2.0 million, respectively. Depreciation expense for the three and six months ended June 30, 2018 was $0.9 million and $1.7 million, respectively.
3. Accrued Expenses
Accrued expenses consist of the following (in thousands):
|
|
As of
|
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2019
|
|
|
2018
|
|
Payroll and employee-related costs
|
|
$
|
5,604
|
|
|
$
|
7,321
|
|
Research costs
|
|
|
9,266
|
|
|
|
7,973
|
|
Licensing fees
|
|
|
—
|
|
|
|
625
|
|
Professional fees
|
|
|
2,096
|
|
|
|
1,848
|
|
Intellectual property costs
|
|
|
1,164
|
|
|
|
2,193
|
|
Accrued property and equipment
|
|
|
387
|
|
|
|
294
|
|
Other
|
|
|
111
|
|
|
|
598
|
|
Total
|
|
$
|
18,628
|
|
|
$
|
20,852
|
|
7
4. Commitments and Contingencies
Litigation
In the ordinary course of business, the Company is from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements, employment and other matters. While the outcome of those proceedings and claims cannot be predicted with certainty, the Company is not party to any legal or arbitration proceedings that may have significant effects on its financial position. It is not a party to any material proceedings in which any director, member of executive management or affiliate of the Company is either a party adverse to it or its subsidiaries or has a material interest adverse to it or its subsidiaries.
As disclosed in its Current Report on Form 8-K filed with the SEC on June 26, 2019, on June 25, 2019, the Company received notification that the United States Patent and Trademark Office initiated an interference proceeding at the Patent Trial and Appeal Board (the “PTAB”) between certain pending U.S. patent applications co-owned by the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively, the “CVC Group”) and certain patents and a patent application currently owned by the Broad Institute and Massachusetts Institute of Technology and, in some instances, the President and Fellows of Harvard College (individually and collectively, the “Broad”), all of which are related to the single guide format of CRISPR/Cas9 genome editing technology in eukaryotic cells. The Company has an exclusive worldwide license in the field of human therapeutics to Dr. Charpentier’s rights as a co-owner of the CVC Group portfolio. Specifically, the PTAB has declared Patent Interference No. 106,115 between the CVC Group’s pending U.S. Patent Application Nos. 15/947,680; 15/947,700; 15/947,718; 15/981,807; 15/981,808; 15/981,809; 16/136,159; 16/136,165; 16/136,168; and 16/136,175, and the Broad’s U.S. Patent Nos. 8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; 8,999,641; 9,840,713, and U.S. Patent Application No. 14/704,551.
Letters of Credit
As of June 30, 2019, the Company had restricted cash of $3.9 million representing letters of credit securing the Company’s obligations under certain leased facilities in Cambridge, Massachusetts, as well as certain credit card arrangements. The letters of credit are secured by cash held in a restricted depository account. The cash deposit is recorded in restricted cash in the accompanying consolidated balance sheet as of June 30, 2019.
Research Agreements
The Company has engaged several research institutions and companies to identify new delivery strategies and applications of its gene-editing technology. The Company is also a party to a number of research license agreements which require significant upfront payments, future royalty payments and potential milestone payments from time to time, as well as intellectual property agreements, which require maintenance and milestone payments from time to time. In association with these agreements, the Company has committed to making payments of $1.7 million and $2.1 million in 2019 and 2020, respectively. For the three and six months ended June 30, 2019, the Company paid $0.5 million and $2.2 million, respectively, related to these research agreements.
The Company is also a party to a number of manufacturing agreements that require upfront payments for the future performance of services. In connection with these agreements, the Company paid $2.8 million in upfront payments, which were recorded as prepaid expenses as of June 30, 2019. The Company will amortize the prepaid balance as services are performed.
5. Leases
In June 2015, the Company entered into a lease agreement for the lease of approximately 19,817 square feet of research facility space with a commencement date of November 15, 2015 (the “2015 Lease”). The lease expires in February 2022. The 2015 Lease contains escalating rent clauses which require higher rent payments in future years.
With the adoption of ASC 842, the Company has recorded a right-of-use asset and corresponding lease liability.
In May 2016, the Company entered into a sublease agreement for its primary office and research facility in Cambridge, Massachusetts, with a commencement date of December 23, 2016 (the “2016 Sublease”). The sublease expires in December 2026, and the Company has an option to extend the term of sublease for an additional five-year period if, at the time of expiration of the initial term, the sublessor does not intend to utilize the space for itself or its affiliates. The 2016 Sublease contains escalating rent clauses which require higher rent payments in future years.
With the adoption of ASC 842, the Company has recorded a right-of-use asset and corresponding lease liability. The right-of-use asset and corresponding lease liability does not include the additional five-year period under the option.
8
In May 2019, the Company entered into a lease agreement for the lease of approximately 15,877 square feet of office facility space with a commencement date of June 1, 2019 (the “2019 Lease”). The lease expires in November 2026, and the Company has an option to extend the term of the lease for an additional five-year period based on certain conditions within the Company’s control. The 2019 Lease contains escalating rent clauses which require higher rent payments in future years. At lease commencement, the Company recorded a right-of-use asset and corresponding lease liability.
The right-of-use asset and corresponding lease liability does not include the additional five-year period under the option.
In addition, the Company rents certain office space in Zug, Switzerland, on a short-term basis for which a right-of-use asset and liability are not recorded, in accordance with the practical expedient elected.
The Company has embedded leases in certain research and license agreements for which the Company has recorded a right of use asset and liability. These arrangements are not significant in comparison to the Company’s total operating lease assets and liabilities. In addition, the Company has identified certain short-term leases embedded within its manufacturing contracts which are not recorded on the Company’s balance sheet in accordance with the practical expedient elected.
The Company identified and assessed the following estimates in recognizing the right-of-use asset and corresponding liability:
|
•
|
Expected lease term
: The expected lease term for those leases commencing prior to January 1, 2019 did not change with the adoption of ASC 842. The expected lease term for leases commencing after the adoption of ASC 842 includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.
|
|
•
|
Incremental borrowing rate
: As the discount rates in the Company’s lease are not implicit, the Company estimated the incremental borrowing rate based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term.
|
The following table summarizes the lease assets and liabilities as of June 30, 2019 (in thousands):
|
|
As of June 30, 2019
|
|
Assets
|
|
|
|
|
Operating lease assets
|
|
$
|
30,770
|
|
Total lease assets
|
|
|
30,770
|
|
Liabilities
|
|
|
|
|
Current
|
|
|
|
|
Operating lease liabilities
|
|
|
4,880
|
|
Non-current
|
|
|
|
|
Operating lease liabilities, net of current portion
|
|
|
37,200
|
|
Total lease liabilities
|
|
$
|
42,080
|
|
The following table summarizes operating lease costs included in research and development and general and administrative expense, as well as sublease income for the three and six months ended June 30, 2019 (in thousands):
|
|
Three months ended June 30,
2019
|
|
|
Six months ended June 30,
2019
|
|
Operating lease costs
|
|
$
|
1,904
|
|
|
$
|
3,726
|
|
Short-term lease costs
|
|
|
1,123
|
|
|
|
2,261
|
|
Variable lease costs
|
|
|
683
|
|
|
|
1,413
|
|
Sublease income
|
|
|
—
|
|
|
|
(525
|
)
|
Net lease cost
|
|
$
|
3,710
|
|
|
$
|
6,875
|
|
9
The following table summarizes the maturity of undiscounted payments due under lease liabilities and the present value of those liabilities as of June 30, 2019 (in thousands):
|
|
Total
|
|
2019
|
|
$
|
4,419
|
|
2020
|
|
|
8,566
|
|
2021
|
|
|
8,507
|
|
2022
|
|
|
7,345
|
|
2023
|
|
|
7,362
|
|
Thereafter
|
|
|
23,254
|
|
Total
|
|
$
|
59,453
|
|
Present value adjustment
|
|
|
(17,373
|
)
|
Present value of lease liabilities
|
|
$
|
42,080
|
|
The following table summarizes the lease term and discount rate as of June 30, 2019:
|
|
As of June 30, 2019
|
|
Weighted-average remaining lease term (years)
|
|
|
|
|
Operating leases
|
|
|
7.0
|
|
Weighted-average discount rate
|
|
|
|
|
Operating leases
|
|
|
9.8
|
%
|
The following table summarizes the cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2019 (in thousands):
|
|
Six months ended June 30,
|
|
|
|
2019
|
|
Cash paid for amounts included in the measurement of lease liabilities
|
|
$
|
3,940
|
|
Operating cash flows from operating leases
|
|
$
|
3,940
|
|
6. Significant Contracts
Collaboration Agreement with and Joint Development Agreement with Vertex Pharmaceuticals Incorporated and certain of its subsidiaries
Summary of Agreement
On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the “2015 Collaboration Agreement”) with Vertex Pharmaceuticals Incorporated and certain of its subsidiaries (“Vertex”). The 2015 Collaboration Agreement is focused on the use of the Company’s CRISPR/Cas9 gene editing technology to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. On December 12, 2017, the Company and Vertex entered into Amendment No. 1 to the 2015 Collaboration Agreement (“Amendment No. 1”) and the Joint Development Agreement (the “JDA”). Amendment No. 1, among other things, modified certain definitions and provisions of the 2015 Collaboration Agreement to make them consistent with the JDA and clarified how many options are exercised (or deemed exercised) in connection with certain targets specified under the 2015 Collaboration Agreement. Amendment No. 1 also amended other provisions of the 2015 Collaboration Agreement, including the expiration terms.
In connection with the 2015 Collaboration Agreement, Vertex made a nonrefundable upfront payment of $75.0 million. Under the 2015 Collaboration Agreement, Vertex will fund the discovery activities conducted pursuant to the agreement while retaining options to co-exclusive and exclusive licenses. In December 2017, upon execution of the JDA and Amendment No. 1, Vertex exercised its option to obtain a co-exclusive license to develop and commercialize hemoglobinopathy and beta-globin targets. As such, for potential hemoglobinopathy treatments, including treatments for sickle cell disease, the Company and Vertex will share equally all research and development costs and worldwide revenues. For other targets that Vertex elects to license, Vertex will lead development and global commercialization activities. For each of up to four remaining targets that Vertex elects to license, the Company has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net product sales.
10
In connection with the JDA, the Company received a $7.0 million up-front payment from Vertex and is eligible for a one-time low seven-digit milestone payment upon the dosing of the second patient in a clinical trial with the initial product candidate. The net profits and net losses, as applicable, incurred under the JDA will be shared equally between the Company and Vertex.
Accounting for the 2015 Collaboration Agreement, Amendment No. 1 and JDA
The arrangements include components of a customer-vendor relationship and collaborative arrangements as defined under ASC 808,
Collaborative Arrangements
. The Company applies the guidance of ASC 606,
Revenue from Contracts with Customers
(“ASC 606”) by analogy to the vendor-customer performance obligations of the 2015 Collaboration Agreement and the performance obligations of the JDA subject to ASC 606 as outlined below. The Company applies the guidance of ASC 808 to those elements in which there is a collaboration relationship in which both parties share equally in the risks and rewards of the research and development as outlined below.
Accounting Analysis Under ASC 606
As the overall arrangement was modified in December 2017, the Company elected a practical expedient within ASC 606 that allowed entities to reflect the aggregate effect of all contract modifications when identifying the satisfied and unsatisfied performance obligations for contracts that were modified prior to the adoption of ASC 606. As of the December 2017 contract modification date, the Company concluded the arrangement contained the following performance obligations: (i) the non-exclusive research license; (ii) four material rights representing the option for up to four exclusive licenses to develop and commercialize the collaboration targets; (iii) a combined performance obligation representing the co-exclusive research license, and a development and commercialization license to develop and commercialize hemoglobinopathies and beta-globin targets; and (iv) the performance of research and development (“R&D Services”).
The selling price of each performance obligation was determined based on the Company’s estimated standalone selling price (the “ESSP”). The Company developed the ESSP for all the performance obligations included in the 2015 Collaboration Agreement and JDA with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The ESSP for material rights was determined based on the incremental discount given to Vertex based on the ESSP of the four remaining exclusive licenses and the exercise price paid at the time of exercise.
As the Company has a right to consideration from Vertex in an amount that corresponds directly with the value of the Company’s performance completed to date for the R&D Services, the Company recognizes revenue related to the R&D Services as invoiced, in line with the practical expedient in ASC 606-10-55-18.
The transaction price was comprised of: (i) original upfront payment of $75.0 million, (ii) an upfront payment of $7.0 million under the JDA and (iii) $19.3 million of variable consideration associated with the R&D Services. The R&D Services revenue is recognized as invoiced and specifically allocated to the R&D Services performance obligation. The remaining transaction price of $82.0 million was allocated among the performance obligations using the relative selling price method as follows: (i) a non-exclusive research license: $0.5 million; (ii) a material right to discounts for exclusive licenses for up to four Collaboration Targets: $22.2 million, $18.7 million, $8.4 million and $8.4 million for a total of $57.7 million; and (iii) co-exclusive development and commercialization licenses for hemoglobinopathy and beta-globin targets identified in the JDA and co-exclusive research license for the follow-on products: $23.8 million.
The Company recognized $0.1 million and $0.2 million of revenue related to the collaboration with Vertex for the three and six months ended June 30, 2019, respectively. The Company recognized $0.2 million and $0.4 million of revenue related to the collaboration with Vertex for the three and six months ended June 30, 2018. As of June 30, 2019, there was $57.7 million of non-current deferred revenue related to the collaboration with Vertex compared to $57.8 as of December 31, 2018. The transaction price allocated to the remaining performance obligations is $57.8 million. The remaining performance obligations will be recognized as follows: four material rights to obtain an exclusive commercialization and development license at a point in time, upon exercise; and the non-exclusive research license ratably over/within the remaining research term. As of June 30, 2019, the remaining amount to be recognized for the non-exclusive research license is not significant. R&D Services are recognized as invoiced under the practical expedient and, as such, are not disclosed within the remaining performance obligation balance.
Milestones under the 2015 Collaboration Agreement
The Company evaluated the milestones that may be received in connection with the 2015 Collaboration Agreement and JDA. The first potential milestone the Company will be entitled to receive is the milestone in the JDA to receive a one-time low seven-digit milestone payment upon the dosing of a second patient in a clinical trial with the initial shared product and was fully constrained as of
11
June 30, 2019
.
T
he remaining milestones are predominately related to the development and commercialization of a product resulting from the arrangement and are payable with
respect
to each selected exclusive license which have yet to be exercised and are not currently included in the determination of the transaction price. Each milestone is payable only once per collaboration target, regardless of the number of products directed to such collaboration target that achieve the relevant milestone event. There are
nine
remaining clinical development and regulatory approval milestones which may trigger proceeds of up to $
90.0
million and $
235.0
million, respectively, for each selected exclusive license, and
two
commercial milestones which may trigger proceeds of up to $
75.0
million for each selected exclusive license (which, when combined with the $
10.0
million due upon exercise of the exclusive option and the $
10.0
million development milestone associated with an Investigational New Drug- enabling application, total $
420.0
million for each selected Exclusive License), as follows:
Developmental Milestone Events
|
1.
|
Initiation of the first Clinical Trial of a Product;
|
|
2.
|
Establishment of Proof of Concept for a Product;
|
|
3.
|
Initiation of the first Phase 3 Clinical Trial of a Product;
|
|
4.
|
Acceptance of Approval Application by the U.S. Food and Drug Administration for a Product;
|
|
5.
|
Acceptance of Approval Application by the European Medicines Agency for a Product;
|
|
6.
|
Acceptance of Approval Application by a Regulatory Authority in Japan for a Product;
|
|
7.
|
Marketing Approval in the U.S. for a Product;
|
|
8.
|
Marketing Approval in the EU for a Product; and
|
|
9.
|
Marketing Approval in Japan for a Product.
|
Commercial Milestone Events
|
1.
|
Annual Net Sales for Products with respect to a Collaboration Target exceed $500 million; and
|
|
2.
|
Annual Net Sales for Products with respect to a Collaboration Target exceed $1.0 billion.
|
There is uncertainty that the events to obtain the developmental milestones will be achieved given the nature of clinical development and the stage of the CRISPR/Cas9 technology. Upon exercise of the exclusive license options, developmental milestones will be constrained until the Company is sure that a significant revenue reversal will not occur. Commercial milestones and royalties relate predominantly to a license of intellectual property and are determined by sales or usage-based thresholds. The commercial milestones and royalties are accounted for under the royalty recognition constraint and will be accounted for as constrained variable consideration. The Company applies the royalty recognition constraint for each commercial milestone and will not recognize revenue for each until the subsequent sale of a licensed product (achievement of each) occurs.
Accounting Analysis under ASC 808
The Company identified the following collaborative elements which are accounted for under ASC 808: (i) development and commercialization services for shared products; (ii) R&D Services for follow-on products; and (iii) committee participation. The related impact of the cost sharing associated with research and development is included in research and development expense. Expenses related to services performed by the Company are classified as research and development expense. Payments received from Vertex for partial reimbursement of expenses are recorded as a reduction of research and development expense.
The Company recognized $6.6 million and $13.7 million of research and development expense related to the collaboration with Vertex for the three and six months ended June 30, 2019, respectively. The Company recognized $0.2 million and $0.4 million of research and development expense related to the collaboration with Vertex for the three and six months ended June 30, 2018, respectively. Research and development expense for the three and six months ended June 30, 2019 was net of $3.3 million and $7.8 million of reimbursements from Vertex, respectively. Research and development expense for the three and six months ended June 30, 2018 was net of $3.7 million and $6.9 million of reimbursements from Vertex, respectively.
12
Joint Venture with Bayer Healthcare LLC
On December 19, 2015, the Company entered into an agreement with Bayer Healthcare LLC and its subsidiaries (“Bayer”), to establish a joint venture to focus on the research the development of new therapeutics to cure blood disorders, blindness and congenital heart disease. On February 12, 2016, the Company and Bayer completed the formation of the joint venture entity, Casebia Therapeutics LLP (“Casebia”). Bayer and the Company each received a 50% equity interest in the entity in exchange for their respective contributions to the entity. The Company contributed $0.1 million in cash and licensed its proprietary CRISPR/Cas9 gene editing technology and intellectual property for selected disease indications. Bayer contributed its protein engineering expertise and relevant disease know-how. Under the agreement, Casebia paid the Company $35.0 million in exchange for a worldwide, exclusive license to commercialize the Company’s gene-editing technology specifically for the indications covered by the license. There are no milestone, royalties or other payments due to the Company under this aspect of the agreement. The Company also entered into a separate services agreement with Casebia, under which the Company agreed to provide compensated research and development services.
During 2016, the Company recorded an equity method investment of $36.5 million equal to the fair value of the Company’s interest in Casebia and subsequently recorded unrealized equity method losses for the same amount. The Company has no further contractual obligations to provide cash financing to Casebia and accordingly, no additional losses have been recorded beyond the initial equity amount. Casebia’s net losses were $18.1 million and $32.3 million for the three and six months ended June 30, 2019, respectively. Casebia’s net losses were $13.5 million and $25.8 million for the three and six months ended June 30, 2018, respectively.
Unrecognized equity method losses in excess of the Company’s equity investment in Casebia were $60.5 million and $45.3 million as of June 30, 2019 and December 31, 2018, respectively.
The remaining performance obligations include research and development services, which are recorded as revenue under ASC 606 and cost sharing activities with Casebia related to shared research and technology licenses are accounted for as a cost/profit sharing arrangement under ASC 808, with the related impact of the cost sharing included as research and development expense. During the three and six months ended June 30, 2019, the Company recognized $0.2 million and $0.4 million of revenue, respectively, related to the collaboration with Casebia. During the three and six months ended June 30, 2018, the Company recognized $0.9 million and $2.0 million of revenue, respectively, related to the collaboration with Casebia. During the three and six months ended June 30, 2019, the Company recognized $0.2 million and $0.7 million, respectively, of research and development expense related to the collaboration with Casebia. During the three and six months ended June 30, 2018, the Company recognized $1.2 million and $2.4 million, respectively, of research and development expense related to the collaboration with Casebia. During the three and six months ended June 30, 2019, the Company recognized a loss from equity method investment of $1.0 million and $2.0 million, respectively, related to stock-based compensation expense for Casebia employees. During the three and six months ended June 30, 2018, the Company recognized a loss from equity method investment of $1.2 million and $2.2 million, respectively, related to stock-based compensation expense for Casebia employees.
7. Share Capital
The Company had 55,445,241 authorized common shares as of June 30, 2019, with a par value of CHF 0.03 per share. Included in the authorized common shares as of June 30, 2019 are 5,586 shares of unvested restricted stock awards, 256,989 treasury shares which are legally outstanding but not considered outstanding for accounting purposes and 1,683,609 shares registered and reserved for future issuance. The Company had conditional capital reserved for future issuance of 19,028,428 common shares for employee benefit plans and 4,919,700 common shares for debt instruments as of June 30, 2019. Under Swiss law, authorized share capital consisted of 25,134,003 common shares as of June 30, 2019.
At-the-Market Offering
In August 2018, the Company entered into an Open Market Sale Agreement
SM
with Jefferies LLC (“Jefferies”), under which Jefferies may offer and sell, from time to time, common shares having aggregate gross proceeds of up to $125.0 million. In the first quarter of 2019, the Company began to issue and sell securities under this sales agreement. During the three and six months ended June 30, 2019, the Company sold 732,108 and 1,363,688 common shares, respectively, for net cash proceeds of $28.5 million and $52.5 million, respectively, after deducting commission fees of $0.8 million and $1.6 million, respectively. In addition, the Company paid approximately $0.2 million in stamp taxes related to the securities issued and sold during the three- and six-month period ended June 30, 2019 and accrued an additional $0.5 million for stamp taxes as of June 30, 2019. The Company sold an additional 1,124,952 common shares under this agreement subsequent to June 30, 2019 through July 29, 2019, resulting in net cash proceeds of approximately $52.8 million, after deducting commission fees of approximately $1.2 million.
13
8. Stock-based Compensation
During the three and six months ended June 30, 2019 and 2018, the Company recognized the following stock-based compensation expense (in thousands):
|
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Research and development
|
|
$
|
5,913
|
|
|
$
|
5,167
|
|
|
$
|
10,875
|
|
|
$
|
8,083
|
|
General and administrative
|
|
|
5,273
|
|
|
|
3,157
|
|
|
|
9,982
|
|
|
|
5,823
|
|
Loss from equity method investment
|
|
|
1,012
|
|
|
|
1,153
|
|
|
|
2,037
|
|
|
|
2,244
|
|
Total
|
|
$
|
12,198
|
|
|
$
|
9,477
|
|
|
$
|
22,894
|
|
|
$
|
16,150
|
|
Stock option activity
The following table summarizes stock option activity for the six months ended June 30, 2019 (intrinsic value in thousands):
|
|
Stock
Options
|
|
|
Weighted-Average Exercise Price
|
|
|
Weighted-Average Remaining Contractual Term (years)
|
|
|
Aggregate Intrinsic Value
|
|
Outstanding at December 31, 2018
|
|
|
6,689,311
|
|
|
$
|
25.42
|
|
|
|
8.3
|
|
|
$
|
68,572
|
|
Granted
|
|
|
1,948,773
|
|
|
$
|
36.05
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(263,700
|
)
|
|
$
|
12.23
|
|
|
|
|
|
|
|
|
|
Cancelled or forfeited
|
|
|
(178,518
|
)
|
|
$
|
33.48
|
|
|
|
|
|
|
|
|
|
Outstanding at June 30, 2019
|
|
|
8,195,866
|
|
|
$
|
28.19
|
|
|
|
8.3
|
|
|
$
|
167,076
|
|
Exercisable at June 30, 2019
|
|
|
3,198,255
|
|
|
$
|
19.51
|
|
|
|
7.5
|
|
|
$
|
91,777
|
|
Vested and expected to vest at June 30, 2019
|
|
|
8,195,866
|
|
|
$
|
28.19
|
|
|
|
8.3
|
|
|
$
|
167,076
|
|
The Company estimated the fair value of each stock option award using the Black-Scholes option-pricing model based on the following assumptions:
|
|
Six Months Ended June 30,
|
|
|
|
2019
|
|
|
2018
|
|
Assumptions
|
|
|
|
|
|
|
|
|
Weighted-average expected volatility
|
|
|
69.3
|
%
|
|
|
72.2
|
%
|
Expected term (in years)
|
|
|
6.0
|
|
|
|
6.0
|
|
Risk-free interest rate
|
|
|
2.5
|
%
|
|
|
2.7
|
%
|
Expected dividend yield
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
As of June 30, 2019, total unrecognized compensation expense related to stock options was $104.3 million which the Company expects to recognize over a remaining weighted-average period of 2.9 years.
In May 2018, the Company modified the terms of certain options held by a departing employee. The modification resulted in $2.2 million in stock-based compensation expense recorded during the period.
14
Restricted
s
tock
activity
The following table summarizes restricted stock activity for the six months ended June 30, 2019:
|
|
Restricted Stock
|
|
|
Weighted-
Average
Grant Date
Fair Value
|
|
Unvested balance as of December 31, 2018
|
|
|
327,342
|
|
|
$
|
36.72
|
|
Granted
|
|
|
49,000
|
|
|
|
33.30
|
|
Vested
|
|
|
(24,339
|
)
|
|
|
14.96
|
|
Cancelled or forfeited
|
|
|
(14,000
|
)
|
|
|
38.33
|
|
Unvested balance as of June 30, 2019
|
|
|
338,003
|
|
|
$
|
37.72
|
|
As of June 30, 2019, total unrecognized compensation expense related to unvested restricted common shares was $8.0
million which the Company expects to recognize over a remaining weighted-average vesting period of 1.35 years.
9.
Net Loss Per Share Attributable to Common Shareholders
Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to common shareholders by the weighted-average number of common share equivalents outstanding for the period, including any dilutive effect from outstanding stock options and warrants using the treasury stock method.
The following common share equivalents, presented on an as-converted basis, were excluded from the calculation of net loss per share for the periods presented due to their anti-dilutive effect (in common share equivalent shares):
|
As of
|
|
|
June 30, 2019
|
|
|
June 30, 2018
|
|
Outstanding options
|
|
8,195,866
|
|
|
|
6,617,181
|
|
Unvested restricted common shares
|
|
338,003
|
|
|
|
169,930
|
|
Total
|
|
8,533,869
|
|
|
|
6,787,111
|
|
10. Income Taxes
During the three and six months ended June 30, 2019, the Company recorded an income tax provision of $0.1 million and $0.2 million, respectively, representing an effective tax rate of -0.2% and -0.2%, respectively. During the three and six months ended June 30, 2018, the Company recorded an income tax provision of $0.1 million and $0.2 million, respectively, representing an effective tax rate of -0.3% and -0.3%, respectively. The income tax provision is primarily attributable to the year-to-date pre-tax income earned by the Company’s U.S. subsidiary. The difference in the statutory tax rate and effective tax rate is primarily a result of the jurisdictional mix of earnings and losses that are not benefited. The Company maintains a valuation allowance against certain deferred tax assets that are not more-likely-than-not realizable. As a result, the Company has not recognized a tax benefit related to losses generated in Switzerland in the current periods.
11. Related Party Transactions
In the fourth quarter of 2018, upon becoming an owner of record of more than 10% of the voting interest of the Company, Vertex became a related party under ASC 850,
Related party disclosures
. Refer to Note 6,
“Collaboration Agreement with and Joint Development Agreement with Vertex Pharmaceuticals Incorporated and certain of its subsidiaries
”
and “
Joint Venture with Bayer Healthcare LLC
” for discussion of transactions with Casebia and Vertex, related parties.
12. Subsequent Events
In June 2019, the Company and Vertex entered into a series of agreements, which closed on July 23, 2019. The Company entered into a strategic collaboration and license agreement (the “2019 Collaboration Agreement”) with Vertex for the development and commercialization of products for the treatment of Duchenne Muscular Dystrophy (“DMD”) and Myotonic Dystrophy Type 1 (“DM1”). Under the terms of the 2019 Collaboration Agreement, the Company
received an upfront, nonrefundable payment of $175 million. In addition, the Company is eligible to receive potential future payments of up to $825 million based upon the successful
15
achievement of specified research, development, regulatory and commercial milestones for the DMD and DM1 programs.
T
he Company is
also
eligible to receive tiered royalties on future net sales on any products that may result from this collaboration. For the DMD program, Vertex is responsible for all research, development, manufacturing and commercialization activities and all related costs. For the DM1 program,
the Company
and Vertex will share research costs for specified guide RNA research to be conducted by the Company, and Vertex is responsible for all other research, development, manufacturing and commercialization costs.
Upon
Investigational New Drug application filing, the Company has the option to forego the DM1 milestones and royalties to co-develop and co-commercialize all DM1 products globally
.
In connection with the execution of the 2019 Collaboration Agreement, the Company and Vertex entered into a second amendment to the 2015 Collaboration Agreement (“Amendment No. 2”). Among other things, Amendment No. 2 modified certain definitions and provisions of the 2015 Collaboration Agreement to make them consistent with the 2019 Collaboration Agreement and set forth the final number and identity of the collaboration targets under the 2015 Collaboration Agreement. The Company and Vertex agreed that one of the four remaining options under the 2015 Collaboration Agreement, as amended, would not be exercised; instead, the Company will conduct research and development activities for a specified target. Vertex will have the option to co-develop and co-commercialize the specified target and if Vertex does not exercise its option to do so within a specified time period, Vertex is eligible to receive potential specified research, development, regulatory and commercial milestones and tiered single-digit royalties on future net sales.
16